Agnieszka Pluta

Agnieszka Pluta

Auto-generated profile, based on publicly available information

Agnieszka Pluta

Department of Hematology, Medical University of Lodz

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
KKKinga Michalina Krawiec
Kinga Michalina Krawiec
PSPiotr Strzałka
Piotr Strzałka
MCMagdalena Czemerska
Magdalena Czemerska
AWAneta Wiśnik
Aneta Wiśnik
IZIzabela Zawlik
Izabela Zawlik
APAgnieszka Pluta
Agnieszka Pluta
More than 97% of patients with acute myeloid leukemia (AML) demonstrate genetic mutations leading to excessive proliferation combined with the evasion of regulated cell death (RCD). The most prominent and well-defined form of RCD is apoptosis, which serves as a defense mechanism against the emergence of cancer cells. Apoptosis is regulated in part by the BCL-2 family of pro- and anti-apoptotic proteins, whose balance can significantly determine cell survival. Apoptosis evasion plays a key role in tumorigenesis and drug resistance, and thus in the development and progression of AML. Research on the structural and biochemical aspects of apoptosis proteins and their regulators offers promise for new classes of targeted therapies and strategies for therapeutic intervention. This review provides a comprehensive overview of current AML treatment options related to the mechanism of apoptosis, particularly its mitochondrial pathway, and other promising concepts such as neddylation. It pays particular attention to clinically-relevant aspects of current and future AML treatment approaches, highlighting the molecular basis of individual therapies.

15 July 2021 in Biology
Verified
Journal Article
Open access
PDF file
MNMateusz Nowicki
Mateusz Nowicki
JSJanusz Szemraj
Janusz Szemraj
AWAgnieszka Wierzbowska
Agnieszka Wierzbowska
APAgnieszka Pluta
Agnieszka Pluta
OGOlga Grzybowska-Izydorczyk
Olga Grzybowska-Izydorczyk
ASAnna Szmigielska-Kapłon
Anna Szmigielska-Kapłon
MicroRNAs play an important role in the regulation of gene expression, cell fate, hematopoiesis, and may influence the efficacy of CD34+ cell mobilization. The present study examines the role of hsa-miR-15a-5p, hsa-miR-16-5p, hsa-miR-34a-5p, hsa-miR-126-3p, hsa-miR-146a-5p, hsa-miR-155-5p, and hsa-miR-223-3p in the course of hematopoietic stem cell mobilization. The numbers of CD34+ cells collected in patients with hematological malignancies (39 multiple myelomas, 11 lymphomas) were determined during mobilization for an autologous hematopoietic stem cell transplantation. The miRNA level was evaluated by RT-PCR. Compared to baseline, a significant decline in hsa-miR-15a-5p, hsa-miR-16-5p, hsa-miR-126-3p, hsa-miR-146a-5p, and hsa-miR-155-5p was observed on the day of the first apheresis (day A). An increase was observed only in the expression of hsa-miR-34a-5p. On day A, a negative correlation was found between hsa-miR-15a-5p and hsa-miR-146a-5p levels and the number of CD34+ cells in peripheral blood. A negative correlation was observed between hsa-miR-146a-5p and the number of collected CD34+ cells after the first apheresis. Good mobilizers, defined according to GITMO criteria, demonstrated a lower hsa-miR-146a-5p level on day A than poor mobilizers. Patients from the hsa-miR-146a-5p “low expressors” collected more CD34+ cells than “high expressors”. Our results suggest that the investigated miRNAs, especially hsa-miR-146a-5p, may influence the efficacy of HSC mobilization.

17 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
PSPiotr Strzałka
Piotr Strzałka
KKKinga Michalina Krawiec
Kinga Michalina Krawiec
AWAneta Wiśnik
Aneta Wiśnik
DJDariusz Jarych
Dariusz Jarych
MCMagdalena Czemerska
Magdalena Czemerska
AWAgnieszka Wierzbowska
Agnieszka Wierzbowska
Acute myeloid leukemia (AML) corresponds to a heterogeneous group of clonal hematopoietic diseases, which are characterized by uncontrolled proliferation of malignant transformed myeloid precursors and their inability to differentiate into mature blood cells. The prognosis of AML depends on many variables, including the genetic features of the disease. Treatment outcomes, despite the introduction of new targeted therapies, are still unsatisfactory. Recently, there have been an increasing number of reports on enzymatic proteins of the sirtuin family and their potential importance in cancer in general. Sirtuins are a group of 7 (SIRT1-7) NAD+-dependent histone deacetylases with pleiotropic effects on metabolism, aging processes, and cell survival. They are not only responsible for post-translational modification of histones but also play various biochemical functions and interact with other proteins regulating cell survival, such as p53. Thus, their role in key mechanisms of tumorigenesis makes them a worthwhile topic in AML. Different sirtuins have been shown to act oppositely depending on the biological context, the mechanism of which requires further exploration. This review provides a comprehensive description of the significance and role of sirtuins in AML in light of the current state of knowledge. It focuses in particular on molecular mechanisms regulated by sirtuins and signaling pathways involved in leukemogenesis, as well as clinical aspects and potential therapeutic targets in AML.

17 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
PSPiotr Strzałka
Piotr Strzałka
KKKinga Michalina Krawiec
Kinga Michalina Krawiec
AWAneta Wiśnik
Aneta Wiśnik
DJDariusz Jarych
Dariusz Jarych
MCMagdalena Czemerska
Magdalena Czemerska
AWAgnieszka Wierzbowska
Agnieszka Wierzbowska
Acute myeloid leukemia (AML) corresponds to a heterogeneous group of clonal hematopoietic diseases, which are characterized by uncontrolled proliferation of malignant transformed myeloid precursors and their inability to differentiate into mature blood cells. The prognosis of AML depends on many variables, including the genetic features of the disease. Treatment outcomes, despite the introduction of new targeted therapies, are still unsatisfactory. Recently, there have been an increasing number of reports on enzymatic proteins of the sirtuin family and their potential importance in cancer in general. Sirtuins are a group of 7 (SIRT1-7) NAD+-dependent histone deacetylases with pleiotropic effects on metabolism, aging processes, and cell survival. They are not only responsible for post-translational modification of histones but also play various biochemical functions and interact with other proteins regulating cell survival, such as p53. Thus, their role in key mechanisms of tumorigenesis makes them a worthwhile topic in AML. Different sirtuins have been shown to act oppositely depending on the biological context, the mechanism of which requires further exploration. This review provides a comprehensive description of the significance and role of sirtuins in AML in the light of the current state of knowledge. It focuses in particular on molecular mechanisms regulated by sirtuins and signaling pathways involved in leukemogenesis, as well as clinical aspects and potential therapeutic targets in AML.

3 December 2015 in Blood
Verified
Journal Article
Open access
AWAgnieszka Wierzbowska
Agnieszka Wierzbowska
EWEwa Wawrzyniak
Ewa Wawrzyniak
APAgnieszka Pluta
Agnieszka Pluta
Ewa RobakEwa Robak
Ewa Robak
GMGrzegorz Mazur
Grzegorz Mazur
HKHagop M. Kantarjian
Hagop M. Kantarjian
Background: Cytogenetics is one of the most important prognostic factors in acute myeloid leukemia (AML). Monosomal karyotype (MK), defined as two or more distinct autosomal monosomies or one single autosomal monosomy in the presence of at least one structural abnormality, has been identified as a new cytogenetic category associated with particularly poor prognosis (Breems, JCO, 2008). AML patients (pts) with MK+ have shorter overall survival (OS) compared to other unfavorable karyotypes, irrespective of treatment intensity. However, preliminary results from a phase II trial of decitabine (DEC) as first-line treatment for elderly AML pts demonstrated that an objective response rate (CR+PR) in MK+ pts was higher than in the MK- cases with abnormal cytogenetics. Moreover, the OS of MK+ pts was comparable to that of MK- pts (Lübbert, Haematologica, 2012). This observation might suggest a positive effect of DEC in patients with MK+ AML. Objective: To determine the effects of treatment with DEC vs low-dose cytarabine or best supportive care (BSC) as a treatment of choice (TC) on OS, progression free survival (PFS) and response rate (CR/CRp) in the subset of pts with AML MK+, who were treated in the randomized phase III DACO-16 study. A second objective is to compare the OS, PFS and CR/CRp of MK+ vs other unfavorable karyotype cases. Methods: Eligible pts were ≥65 years old with newly diagnosed, de novo or secondary AML with ≥20% bone marrow blasts, ECOG performance status 0-2, WBC count ≤40x109/L. According to study protocol pts were randomly assigned 1:1 to receive DEC 20 mg/m2 per day as a 1-hour i.v. infusion for five days every 4 weeks or TC (BSC or cytarabine 20 mg/m2 s.c. for 10 days every 4 weeks). This analysis included pts identified from the clinical database whose locally obtained cytogenetics data indicated they had MK+. Pts with poor-risk cytogenetics (Southwest Oncology Group classification) but MK- (poor-risk MK-) were used as the comparison group. Median OS (Kaplan-Meier method) and PFS were compared between decitabine vs TC treatment arms for pts MK+ and poor-risk MK-. Remission was assessed using modified IWG AML criteria (Cheson, Blood, 2003). Results: Of 480 pts in DACO-16 study, 64 (13.3%) fulfilled the criteria for MK+ and additional 99 (20.6%) had poor-risk MK- cytogenetics. In MK+ group 33 pts received DEC and 31 pts were assigned to TC. In poor-risk MK- group DEC and TC was administered to 49 and 50 pts respectively. Baseline characteristics of treatment subgroups were comparable. Outcome of MK+ and poor-risk MK- pts according to treatment arm The CR/CRp rate in MK+ pts was higher in the DEC arm compared to TC (21% vs 3%; OR=8.1; 95% CI, 0.93 to 70.04; P = 0.054). The median PFS was also improved in the DEC arm vs TC (2.6 vs 1.3 mos, HR=0.53; 95% CI, 0.31 to 0.9; P = 0.018) Fig.1. There was a trend towards longer OS by ~4 mos in the DEC arm vs TC (2.6 vs 6.3 mos; HR=0.67; 95% CI, 0.39 to 1.15; p=0.14) Fig.2. In contrast, no difference in CR/CRp rate between DEC vs TC was observed in poor-risk MK- pts (respectively 8% vs 10%; OR=0.8; 95% CI, 0.2 to 3.17; P = 1.0). Similarly, no improvement in PFS as well as OS was observed in poor-risk MK- cases treated with DEC compared to TC. Overall survival in decitabine and TC treatment arms according to cytogenetics In AML patients receiving low-dose cytarabine or BSC, patients with MK+ appeared to have a poorer outcome than pts with poor-risk MK-. The median OS was 2.6 vs 4.7 mos (HR=1.52; 95% CI, 0.91 to 2.54; p=0.11) in MK+ and poor-risk MK- pts, respectively. In contrast, in the DEC arm MK+ pts did not do worse than MK- cases with poor-risk cytogenetics. The median OS was similar: 6.3 vs 5.0 mos for MK+ and poor-risk MK- (HR=0.98; 95% CI, 0.6 to 1.58; p=0.92), respectively. Conclusions: In older patients with AML-MK+, decitabine improved CR/CRp rate and PFS compared with standard therapies. A survival analysis suggesting a benefit of about 4 months in median OS for decitabine in MK+ AML needs confirmation in further studies with larger sample size. These data might suggest decitabine overcomes the extremely poor prognosis associated with MK and may be a beneficial initial treatment as an alternative to low-dose cytarabine or best supportive care. Figure 1. PFS of patients with AML MK+ according to treatment Figure 1. PFS of patients with AML MK+ according to treatment Figure 2. OS of patients with AML MK+ according to treatment Figure 2. OS of patients with AML MK+ according to treatment Disclosures: Wierzbowska: Janssen, Celgene: Consultancy. Off Label Use: Decitabine in elderly AML patients. Robak:Eisai Inc: Research Funding. Oriol:Celgene, Janssen, Amgen: Consultancy, Speakers Bureau.

2 December 2016 in Blood
Verified
Journal Article
Open access
MNMateusz Nowicki
Mateusz Nowicki
JSJanusz Szemraj
Janusz Szemraj
AWAgnieszka Wierzbowska
Agnieszka Wierzbowska
MMMałgorzata Misiewicz
Małgorzata Misiewicz
RMRoman Małachowski
Roman Małachowski
ASAnna Szmigielska-Kaplon
Anna Szmigielska-Kaplon
Introduction MicroRNAs are a class of small (19-25 nucleotides), endogenous RNA which play a significant role in regulation of gene expressions, cell proliferation, differentiation, apoptosis. These class of small molecules, engaged in angiogenesis and hematopoiesis can influence hematopoietic stem cells (HSC) homing after transplantation by targeting bone marrow niche microenvironment. The aim of the study was to evaluate expression of miRNA-15a, miRNA-16 (engaged in angiogenesis, apoptosis, proliferation and differentiation of HSC) miRNA-126, miRNA-146a (regulating homing of HSC after transplantion) and miRNA-223 (involved in apoptosis and granulopoiesis) in patients with lymphoproliferative malignancies prior to autologous hematopoietic stem transplantation (HSCT) and in early posttransplant period. Patients Fifty one patients were enrolled to the study (23 F, 28 M). The median (Me) age was 59 years. The investigated group consisted of 42 multiple myeloma (7 CR, 27 VGPR, 8 PR), 7 non-Hodgkin lymphoma (3 CR, 4 PR), and 2 Hodgkin lymphoma (2 PR). The blood (plasma samples) were collected on 4 time points: before chemotherapy - "BC", on the day of HSCT (after chemotherapy) - "0", seven days after HSCT "N" (nadir) - "N" and fourteen days after HSCT - "+14". Methods Total RNA was isolated using miRNeasy Serum/Plasma KIT (Qiagen, Hilden, Germany). MiRNA conversion to cDNA was performed using TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA). We used TaqMan MicroRNA Assays (Applied Biosystems): has-miR-15a-5p, has-miR-15a-5p, has-miR-146a-5p, has-miR-126-3p and has-miR-223-3p primers) to detect mature miRNA. Reverse transcription conditions were normalized using 5 nmol mirVana miRNA Mimic (cel-miR-39) as an endogenous control (Ambion, Austin, TX). The miRNA level was evaluated by Real Time PCR method. The Wilcoxon matched-pairs test was used to compare groups of dependent continuous variables: miRNA's RQ levels at two different time points. Spearman rank correlation coefficient (R) was used to compare independent variables: regeneration and miRNA's RQ level. Comparisons and correlations were considered significant if p<0.05. Results Kinetics of miRNA before conditioning treatment and after HSCT Our research revealed significant, steady decline of miRNA-15a, miRNA-16, miRNA-126, miRNA-146a and miRNA-223 at all time points as compared to baseline (BC). We observed increased miRNA-126 and miRNA-223 expression on "+14" day as compared to "N" day (Tab. 1). Correlation between miRNA expression and regeneration We observed that higher level of investigated miRNAs after chemotherapy resulted in longer time to engraftment. Our research revealed positive correlation between miRNA-15a, miRNA-16, miRNA-126 and miRNA146a levels on "0' day and the time to engraftment (R=0.36, p=0.009), (R=0.41, p=0.003), (R=0.30, p=0.03), (R=0.29, p=0.03) respectively. Additionally we found positive correlation between levels of miRNA-15a, miRNA-146a and miRNA-223 assessed on "N" day and time of regeneration (R=0.33, p=0.02), (R=0.34, p=0.02) and (R=0.30, p=0.04) respectively. No correlation between expression of all investigated miRNAs before chemotherapy and time to engraftment was found. Conclusions In conclusion, all investigated miRNAs changed significantly after conditioning treatment. Low expression of miRNA-15a and miRNA-16, as HSC proliferation and angiogenesis factors, play important role in regeneration process after chemotherapy and in early post-transplant period. Low expression of miRNA-223 on nadir day correlates with faster engraftment, which is probably related with miRNA-223 activity on different stages of hematopoietic cells development, especially myeloid precursors differentiation and maturation. Effective regeneration, correlated with decreased miRNA-126, miRNA-146a level after conditioning treatment, may be affected by well-known homing processes regulated by VCAM-1 and CXCR4/SDF-1 signaling. We suggest that investigated miRNAs expression in the early post-transplant period is significant for time to engraftment after HSCT.